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Abstract
The role of chemokines in chronic hepatitis C virus (HCV) infection is not fully understood. The present study aimed to characterize
the baseline serum concentrations and the initial b-chemokine response to treatment with interferon-a and ribavirin with respect to
the ﬁnal clinical outcome of virological response to treatment. Serum concentrations of alanine aminotransferase (ALT) and of the CC
subfamily chemokines [macrophage inﬂammatory protein (MIP)-1a, MIP-1b, monocyte chemoattractant protein (MCP)-1 and the regu-
lated on activation, normal T expressed and secreted (RANTES) chemokine] were measured in patients with chronic HCV infection
and in healthy individuals. Necroinﬂammation and ﬁbrosis were scored in liver biopsies. Treatment outcomes were classiﬁed as with or
without a sustained virological response after a full-course treatment according to the genotypes. The main treatment group consisted
of 72 patients with chronic hepatitis C, whereas 24-h blood samples were available for 42 patients. Increased baseline levels of all CC
chemokines were found in the two responder groups compared to the healthy controls, although signiﬁcant levels were reached only
for MIP-1a and MCP-1. No correlation was observed between chemokine levels and serum ALT levels, any histological necroinﬂamma-
tory parameters, or the ﬁbrosis grade. After 24 h of treatment, increases in MIP-1a, MIP-1b and RANTES levels were exclusively
observed in the group with sustained virological response. MCP-1 was also signiﬁcantly increased after 24 h in both responder groups,
although no differences were observed between the two responder groups. In conclusion, an early MIP-1a, MIP-1b, and RANTES
response may predict a sustained response to virological treatment.
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Introduction
The understanding of successful virus elimination mediated by
the immune response to hepatitis C virus (HCV) infection is
far from settled. Both viral and host factors are determinants
for the spontaneous elimination or persistence of the virus. In
HCV infection, some 50–90% of the patients develop chronic
disease [1]. There is evidence that unspeciﬁc CD8 cells and a
subset of antigen-speciﬁc CD4 cells deviating T-helper cells in
a TH1 proﬁle (interferon (IFN) and tumour necrosis factor-a)
play a pivotal role in the immune response to the HCV [2].
A rapid and strong host T cell response plays a major role
in effective clearance of the HCV virus. Most likely, the ten-
dency towards chronic infection represents a lack of a strong
and speciﬁc immune response to viral antigens as well as an
ineffective rapid clearance of the HCV [3,4].
The recruitment of effector cells from the blood stream
to the liver is dependent upon local chemokines and their
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receptors. Chemokines constitute a large family of small
proteins consisting of four main subfamilies (CXC, CC, C,
CX3C) mediating their effects on a family of seven-trans-
membrane domain G-protein coupled receptors [5]. The
chemokines are responsible for the leukocyte migration by
creating a chemical gradient from the vascular endothelium
to the infected cells [6] and by selective expressions of dif-
ferent chemokine receptors on the leukocytes [7].
There is increasing evidence for a role of chemokines as
inﬂammatory mediators in HCV infection [8].
The CC chemokines macrophage inﬂammatory protein
(MIP)-1a (CCL3), MIP-1b (CCL4) and the regulated on activa-
tion, normal T expressed and secreted (RANTES) chemokine
(CCL5) are expressed by the portal vessel endothelium and
recruit macrophages and lymphocytes into the liver [6,9].
These chemokines bind to their corresponding receptors,
CCR5, on lymphocytes with type 1 cytokine secretion [9,10].
Theoretically, both the chemokine response to HCV and the
availability of the corresponding receptors on the lymphocytes
are obligatory for a strong immunological response to the
virus. Genetically determined loss of CCR5 expression has
been linked to chronic hepatitis [11]. Most studies, although
not all, have shown increased intrahepatic and/or blood levels,
as well as increased expression, of the CXC and CC families
of chemokines in chronic HCV infection [8]. However, the
exact role of chemokines both in spontaneous remission and
in response to immunomodulatory agents such as IFN-a is so
far poorly understood. According to the few studies available,
high baseline serum levels of MIP-3a [12] are associated with a
positive prognostic response, whereas high levels of IFN-c-
inducible protein 10 are associated with a negative prognostic
response to treatment [13,14]. Moreover, increase in CXCR3-
expressing CD8+ cells during treatment has been associated
with achievement of virus control [15]. However, the dynamics
of the apparent critical initial rapid CC chemokine response with
emphasis on clearance of virus is so far not well investigated.
Therefore, in the present study, we describe the blood
concentrations of MIP-a, MIP-b, monocyte chemoattractant
protein (MCP)-1 and RANTES and their relationship to liver
enzyme levels, microbiological and histological parameters at
baseline, and then describe the association between the ini-
tial (24 h) chemokine response and the ﬁnal clinical outcome
of the treatment of chronic HCV infection.
Materials and Methods
Patients
Seventy-two patients with chronic HCV infection were
included. The patients were admitted to the University
Hospital of North Norway, Tromsø, and Nordland Hospital,
Bodø, Norway, for diagnosis and treatment between 1998
and 2005. Blood tests were made for alanine aminotransfer-
ase (ALT), chemokines and HCV at admission (all 72
patients) and after 24 h (42 patients).
The inclusion criteria for treatment were elevated ALT,
positive HCV serology and viraemia as detected by PCR.
Patients with concomitant active hepatitis B virus infection
and patients with severe diseases were excluded.
Patients included before 2001 received IFN-a-2b (Introna;
Schering Plough AS, Oslo, Norway), 3 million international
units thrice weekly (monotherapy). After 2001, treatment
was a combination of pegylated IFN-a-2b (PegIntron, Scher-
ing Plough), 1.5 lg/kg once weekly, and ribavirin (Rebetol,
Schering Plough), 600–1200 mg/day (dual therapy), for either
24 weeks (genotype 2 or 3) or 48 weeks (genotype 1 or 4).
The treatment effect was classiﬁed as sustained virological
response (SVR; negative HCV PCR 24 weeks after cessation
of treatment) and non-SVR [comprising two subgroups:
relapse (negative/positive HCV PCR at the end of treatment
and positive test after an additional 24 weeks, respectively)
and nonresponse (positive HCV PCR after 12 weeks of
treatment)]. The treatment responses among the 72 patients
were SVR in 39 and non-SVR in 33 patients (with 17 cases
of relapse and 16 of nonresponse). Liver biopsies were per-
formed on a regular basis before the start of treatment. The
modiﬁed hepatic activity index (HAI) grading necroinﬂamma-
tory scores (0–18) was determined and ﬁbrosis grading
(0–6) was performed according to Ishak et al. [16].
In Table 1, the baseline characteristics and clinical proﬁles
are presented for the 72 patients (monotherapy, n = 40; dual
therapy, n = 32) included in the study. In 12 patients (all in
the monotherapy group), genotype determination was not
performed as a result of the combination of the unavailability
of the method at the time of inclusion and the lack of blood
for testing at a later time point. Histological examinations of
TABLE 1. Clinical characteristics at baseline of patients
with chronic hepatitis C virus infection grouped according
to response to treatment
All
Sustained
response
Nonsustained
response
n 72 39 (54%) 33 (46%)
Male/female 42/30 22/17 15/18
Age (years) 38 (36–40) 36 (34–38) 41 (36–45)
ALT (U/L) (n = 72) 99 (86–114) 111 (91–135) 87 (72–106)
HAI index (n = 65) 9.0 (8.3–9.8) 8.4 (7.4–9.3) 10.0 (8.9–11.0)
Fibrosis score (n = 65) 1.5 (1.1–1.8) 1.4 (1.0–1.8) 1.6 (1.0–2.2)
Genotype 1:2:3:4 (n = 60) 26:4:27:3 6:4:16:1 20:0:11:2
Data are presented as the mean (95% CI) (for ALT geometric mean) or n (%).
ALT, aminotransferase; HAI, hepatic activity index.
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liver biopsies were performed in 65 patients. In seven
patients, biopsy specimens were not available, either because
of patient refusal to participate or because of a regular,
missed biopsy. Regarding the 24-h analyses, only blood sam-
ples from 42 patients were available [SVR, n = 23; non-SVR,
n = 19 (relapse, n = 12; nonresponse, n = 7)].
Analysis of chemokines
Serum from blood samples was obtained after centrifugation
at 4C and subsequently kept at )27C. Measurement of the
CC chemokines MIP-1a, MIP-1b, MCP-1 and RANTES was
performed with commercial ELISA kits (Quantikine,
human chemokines; R&D Systems Europe Ltd, Oxon, UK).
Blood samples from ﬁve healthy volunteers were used as
controls.
Approvals
All participants provided their written informed consent. The
Regional Committee for Medical and Health Research Ethics
approved of the study, and permissions for storage of biolog-
ical material and the research database were granted from
the Norwegian Ministry of Health and the Norwegian Social
Science Data Services (NSD), respectively.
Statistical analysis
Unless otherwise stated, data are presented as the mean
(95% CI). For log-linear variables (chemokine and ALT mea-
surements), geometric means were used. For further analy-
ses, logarithmic transformation was used when appropriate.
Ordinal variables (HAI, ﬁbrosis score) were analyzed using
nonparametric statistics (Wilcoxon test). Correlation statis-
tics were performed by Pearson correlation. Categorical data
were analyzed using a chi-square test. Analysis of basal
chemokine levels was performed by one-way analysis of vari-
ance followed by a simple contrast with healthy controls as
reference. The 0–24-h differences showed normal distribu-
tion, and nontransformed data could be entered into t-test
analysis. Chemokine levels were analyzed comparatively
between groups using Student’s t-test for independent obser-
vations and, within groups, one-sample t-tests were used.
None of the analyses violated the assumption of normal dis-
tribution or the assumption of equality of variances.
Linear and logistic regression analyses were performed to
test for confounding effects of sex, age, type of treatment,
ALT levels, genotype and histological data.
Receiver-operating characteristics (ROC) analysis was per-
formed with 0–24-h differences in chemokine levels as con-
tinuous variable and SVR/non-SVR as the state variable.
All analyses were performed using SPSS software, version
16.0 (SPSS Inc., Chicago, IL, USA).
Results
Clinical characteristics at baseline
In the entire group of 72 patients, no signiﬁcant differences
were detected in ALT levels, HAI scores or ﬁbrosis scores
across the treatment groups with and without SVR (Table 1)
or when further subgrouping according to SVR and the two
non-SVR subgroups (relapsers and nonresponders) (data not
shown). As expected, there was more SVR in the genotype
2 + 3 group than in the genotype 1 + 4 group (p 0.008, chi-
square). Moreover, logistic regression analysis showed that
genotype 1 + 4 (p 0.006), but not age, sex or ALT levels,
were independent predictors of treatment response (SVR vs.
non-SVR).
Baseline chemokines in HCV patients and in healthy
controls
There were increases in all chemokines in the SVR group and
the non-SVR group (relapsers and nonresponders) compared
to healthy controls, but only MIP-1a and MCP-1 levels were at
signiﬁcant levels (Table 2). No signiﬁcant differences were
observed between the various chemokine levels in the various
responder groups (data not shown). When comparing the lev-
els of each of the four chemokines, linear regression analyses
TABLE 2. Serum chemokine con-
centrations at baseline in patients
with chronic hepatitis C virus
infection grouped according clinical
outcome
n
MIP-1a
(pg/mL)
MIP-1b
(pg/mL)
MCP-1
(pg/mL)
RANTES
(ng/mL)
Sustained response 39 7 (3–14)* 77 (56–107) 239 (200–286)* 33 (27–41)
Relapse 17 11 (6–22)* 79 (54–115) 225 (179–284)* 31 (22–43)
Nonresponse 16 5 (1–20) 87 (63–120) 181 (83–398)* 31 (21–47)
Healthy controls 5 1 (0.8–2.0) 64 (33–126) 61 (51–73) 21 (17–26)
p (analysis of variance) 0.003 NS <0.0005 NS
Data are presented as geometric mean (95% CI).
*Signiﬁcant difference from healthy controls by simple contrast.
MCP, monocyte chemoattractant protein; MIP, macrophage inﬂammatory protein; RANTES, regulated on activation,
normal T expressed and secreted.
NS, not signiﬁcant.
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showed no signiﬁcant effects of factors such as ALTlevels, sex,
age, type of treatment, and treatment response on the chemo-
kine levels. Moreover, no signiﬁcant correlations could be
detected between histological and microbiological parameters
vs. chemokine levels (data not shown).
Early chemokine changes during initiation of hepatitis C
treatment
In the group of 42 patients (16 with monotherapy and 26
with dual therapy) with 24-h blood samples available, signiﬁ-
cant increases from baseline (within groups) were exclusively
observed in the SVR group for MIP-1a and MIP-1b, and at a
nonsigniﬁcant level for RANTES (Fig. 1). MCP-1 levels were
signiﬁcantly increased in both responder groups (Fig. 1),
whereas, in the non-SVR group, the signiﬁcant increase was
only observed in the subgroup of relapsers (data not shown).
Moreover, the mean differences between the SVR and non-
SVR groups at 24 h were signiﬁcant (between groups) with
respect to MIP-1a, MIP-1b and RANTES, but not MCP-1
(Fig. 1).
These observed differences in response were also
observed after adjustment for sex, age, genotype and treat-
ment protocol in a linear regression analysis.
ROC analysis
To determine whether the early chemokine response could
predict SVR, an ROC analysis was performed. Only MIP-1a
and MIP-1b had signiﬁcant areas (Fig. 2). A cut-off of 0 pg/mL
0–24 h increase in serum MIP-1a would yield a sensitivity of
approximately 0.8 and a speciﬁcity of 0.5 for virological
response. A cut-off of 0 pg/mL 0–24 h increase in serum
MIP-1b would yield a sensitivity of approximately 0.8 and a
speciﬁcity of 0.4 for SVR.
Discussion
In the present study, we have shown that baseline serum lev-
els of the CC chemokines MIP-1a, MIP-1b, MCP-1 and RAN-
TES were increased compared to healthy controls. There
were no signiﬁcant relationships between the serum levels of
the chemokines and liver function tests, microbiological and
histological parameters. Of the various chemokines studied,
a rapid (24 h) response exclusively associated with a sus-
tained virological response (SVR) was observed only for MIP-
1a, MIP-1b and RANTES. MCP-1 was increased in both the
SVR and non-SVR group, although no differences between
the two responder groups were observed.
In agreement with several previous studies, the serum lev-
els of CC chemokines were increased in patients with
chronic HCV infection compared to healthy controls [8].
Increased intrahepatic expression has also been reported for
CC chemokines [17,18]. Furthermore, in the present study,
serum levels of the CC chemokines were not associated with
the grade of necroinﬂammatory activity or the ﬁbrosis grade.
In the literature, there are conﬂicting results concerning this
topic; in one study, serum MIP-3a and ALT correlated signiﬁ-
cantly [12]; in another study, intrahepatic RANTES expres-
sion correlated well with the histological activity [17],
whereas, in yet another study, the expression of RANTES or
MIP-1b in the liver did not correlate with necroinﬂammation
activity scores [18]. Most likely, during a chronic HCV
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FIG. 1. Early serum chemokine
responses to the treatment of chronic
hepatitis C virus infection. Values are
geometric means (95% CI for geometric
mean); p values are generated by a
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underline) and between group (short
underline) differences.
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infection, there is an inﬂammatory circle: an activated chemo-
kine response is responsible for recruitment of inﬂammatory
cells, which in turn activate further production of cytokines
and chemokines. This inﬂammatory circle is in turn responsi-
ble for the chronic necroinﬂammation and the development
of cirrhosis [13]. However, the exact contribution of chemo-
kines and especially the CC chemokines to this inﬂammatory
circle is unclear and needs further studies.
The conventional treatment of chronic HCV infection
consists of a combination of the immunomodulatory and an-
tiviral agents IFN-a and ribavirin. Several studies have shown
that a rapid viral clearance from the general circulation is
associated with a high rate of sustained virological response
[19]. It has been proposed that the natural immune response
to the HCV has to be rapid, strong and complete with the
various epitopes to prevent virus escape and subsequent
chronic inﬂammation [20]. Therefore, the present study was
designed to study early (24 h) responses of the CC chemo-
kines during the initiation of antiviral treatment. Signiﬁcant
increases exclusively associated with a sustained virological
response were observed for MIP-1a and MIP-1b. For RAN-
TES, the responses at 24 h were less pronounced but were
at signiﬁcant levels between the two groups.
It is of interest to note that MCP-1 levels were also
increased at 24 h of treatment in the sustained response
group and in the relapser group, but not in the nonre-
sponder group. Our data indicate that, of the various chemo-
kines mediating the immune response during the treatment,
MIP-1a, MIP-1b and RANTES, in contrast to MCP-1, appar-
ently play an important role in inducing an effective clearance
of the HCV.
Interestingly, the present data indicate a possible role of
early chemokine response as a predictor of an SVR
response. As can be seen form the ROC curves in Fig. 2, the
assays cannot yield both high sensitivity and speciﬁcity at the
same time because this would require a steep sigmoid curve
shape with an area approaching 1. The clinical use of such a
test would be to decide whether a patient should discon-
tinue treatment, assuming the patient will not respond to
treatment. Consequently, the cut-off values were set for high
sensitivity of response to give the patient the beneﬁt of
doubt.
The present study indicates that various chemokines play
a role in mediating an effective immunomodulatory role dur-
ing treatment of HCV infection. However, the results
obtained must be interpretated with great caution. First, the
number of patients studied was low and two types of treat-
ment with IFN-a were used in the patients studied. Second,
the study was not primarily designed to test independent
24-h chemokine responses to the ﬁnal clinical outcome. A
future study should be prospective and properly stratiﬁed
for potential confounding factors such as sex, genotypes and
grade of liver cirrhosis. In this setting, a possible role of early
chemokine response as a clinical predictor of sustained viro-
logical response could be better evaluated.
In conclusion, serum levels of CC chemokines are ele-
vated in chronic HCV infection but not associated with the
grade of necroinﬂammation. An early response of MIP-1a,
MIP-1b and RANTES to treatment may predict an effective
HCV clearance.
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